Outer membrane vesicles (OMVs) and detoxified lipooligosaccharide (dLOS) obtained from Brazilian prevalent N. meningitidis serogroup B strains protect mice against homologous and heterologous meningococcal infection and septic shock

• Published in: Vaccine 2004-06, Vol.22 (20), p.2617-2625
• Main Authors: Jessouroun, Ellen, da Silveira, Ivna F.B., Larangeira, Andréa P., Pereira, Solange, Fernandes, Solange A., Rabinovitch, Leon, Frasch, Carl E., Castro-Faria-Neto, Hugo C., Bozza, Patricia T.
• Format: Article
• Language: English
• Subjects: Animals; Antibodies, Bacterial - biosynthesis; Applied microbiology; Bacterial Outer Membrane Proteins - administration & dosage; Bacterial Outer Membrane Proteins - analysis; Bacterial Outer Membrane Proteins - immunology; Bacterial Vaccines; Biological and medical sciences; Brazil; Cytokines; Cytokines - blood; Fundamental and applied biological sciences. Psychology; Lipopolysaccharides - administration & dosage; Lipopolysaccharides - immunology; Meningococcal Infections - immunology; Meningococcal Infections - prevention & control; Mice; Microbiology; N. meningitidis vaccines; Neisseria meningitidis; Neisseria meningitidis - immunology; Outer membrane vesicles; Shock, Septic - immunology; Shock, Septic - prevention & control; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2003.12.009

Neisseria meningitidis ( N. meningitidis) is a serious bacterial pathogen that causes life-threatening invasive bacterial infections especially in children below 2 years of age, teenagers and young adults. We have investigated the protective potential of outer membrane vesicles (OMVs) and detoxified lipooligosaccharide (dLOS) obtained from Brazilian prevalent N. meningitidis serogroup B strains. Swiss mice were immunized with different combinations of OMV and dLOS from N. meningitidis serogroup B strains compared to a reference vaccine (VA-MENGOC-BC ®, Cuba). The OMVs + dLOS from Brazilian prevalent strains induced higher bactericidal antibody titers against homologous and heterologous target strains and stronger inhibition of thrombocytopenia as compared to the reference vaccine. When the challenge was performed with the B strain, all immunogens tested showed similar survival rates (80%) significantly higher than the control group. Bacterial clearance against the group B strain was comparable for animals immunized with the tested immunogen and the reference vaccine. Inclusion of dLOS from the B strain with the OMV, induced a similar clearance of C strain bacteria as compared to VA-MENGOC-BC ®. The immunogens, as well as the reference vaccine drastically inhibited increases in TNF-α and IL-6 plasma levels after challenge. In conclusion, the OMV/dLOS formulation obtained from Brazilian prevalent strains of N. meningitidis has a remarkable performance protecting mice against the lethal effects of meningococcal challenge showing a good potential as a vaccine and should be considered for clinical evaluation.